Table 3.

Changes in liver indicators from baseline between groups

Outcome	Placebo (n = 41)	Silymarin (n = 42)	P value
CAP (dB/m)
12 weeks	2.28 ± 6.15	8.78 ± 5.98	0.471
24 weeks	-0.80 ± 6.42	1.84 ± 6.25	0.780
LSM (kPa)
12 weeks	0.43 ± 0.18	-0.09 ± 0.17	0.049
24 weeks	0.41 ± 0.17	-0.21 ± 0.17	0.015
ALT (U/L)
12 weeks	6.48 ± 4.30	-2.52 ± 4.24	0.159
24 weeks	-4.29 ± 4.44	-3.45 ± 4.23	0.896
AST (U/L)
12 weeks	2.30 ± 2.14	-1.85 ± 2.11	0.191
24 weeks	-2.20 ± 2.44	-3.02 ± 2.32	0.816
GGT (U/L)
12 weeks	6.88 ± 2.76	-2.47 ± 2.73	0.024
24 weeks	1.23 ± 3.16	-8.21 ± 3.01	0.042
AST/ALT
12 weeks	-0.06 ± 0.04	0.00 ± 0.04	0.915
24 weeks	-0.03 ± 0.04	0.04 ± 0.04	0.335
Total bilirubin (μmol/L)
12 weeks	-0.11 ± 0.56	0.74 ± 0.56	0.308
24 weeks	1.23 ± 0.74	1.19 ± 0.70	0.968
APRI
12 weeks	0.0004 ± 0.0004	-0.0004 ± 0.0004	0.169
24 weeks	-0.0004 ± 0.0004	-0.0006 ± 0.0004	0.677
FIB-4
12 weeks	-0.02 ± 0.04	-0.02 ± 0.04	0.711
24 weeks	-0.07 ± 0.03	-0.07 ± 0.03	0.969

Data are presented as adjusted means ± SEs. One-way ANCOVA was used to compare the difference in changes from baseline after 12 and 24 weeks of intervention between the groups with adjustment for baseline age and AST/ALT, ApoA1 and SOD concentrations

Abbreviations: CAP controlled attenuation parameter, LSM liver stiffness measurement, ALT alanine aminotransferase, AST aspartate aminotransferase, GGT γ-glutamyl transpeptidase, TG triglycerides, APRI aspartate aminotransferase-to-platelet ratio index, FIB-4 fibrosis index based on 4 factors